Erdosteine

Erdosteine

Clinical data
ATC code	R05CB15 (WHO)
Identifiers
IUPAC name 2-[(2-oxothiolan-3-yl)carbamoylmethylsulfanyl]acetic acid
CAS Number	84611-23-4
PubChem CID	65632
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C8H11NO4S2
Molar mass	249.309 g/mol

WikiDoc Resources for Erdosteine
Articles
Most recent articles on Erdosteine Most cited articles on Erdosteine Review articles on Erdosteine Articles on Erdosteine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Erdosteine Images of Erdosteine Photos of Erdosteine Podcasts & MP3s on Erdosteine Videos on Erdosteine
Evidence Based Medicine
Cochrane Collaboration on Erdosteine Bandolier on Erdosteine TRIP on Erdosteine
Clinical Trials
Ongoing Trials on Erdosteine at Clinical Trials.gov Trial results on Erdosteine Clinical Trials on Erdosteine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Erdosteine NICE Guidance on Erdosteine NHS PRODIGY Guidance FDA on Erdosteine CDC on Erdosteine
Books
Books on Erdosteine
News
Erdosteine in the news Be alerted to news on Erdosteine News trends on Erdosteine
Commentary
Blogs on Erdosteine
Definitions
Definitions of Erdosteine
Patient Resources / Community
Patient resources on Erdosteine Discussion groups on Erdosteine Patient Handouts on Erdosteine Directions to Hospitals Treating Erdosteine Risk calculators and risk factors for Erdosteine
Healthcare Provider Resources
Symptoms of Erdosteine Causes & Risk Factors for Erdosteine Diagnostic studies for Erdosteine Treatment of Erdosteine
Continuing Medical Education (CME)
CME Programs on Erdosteine
International
Erdosteine en Espanol Erdosteine en Francais
Business
Erdosteine in the Marketplace Patents on Erdosteine
Experimental / Informatics
List of terms related to Erdosteine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Erdosteine is a mucolytic. Erdosteine is a thiol derivative developed for the treatment of chronic obstructive bronchitis, including acute infective exacerbation of chronic bronchitis. Erdosteine contains 2 blocked sulfhydryl groups which are released following first-pass metabolism. The 3 active metabolites exhibit mucolytic and free radical scavenging activity. Erdosteine modulates mucus production and viscosity and increases mucociliary transport, thereby improving expectoration. It also exhibits inhibitory activity against the effects of free radicals produced by cigarette smoke. Clinical studies in patients with chronic obstructive lung disease have demonstrated the efficacy and tolerability of erdosteine. Erdosteine 300mg twice daily reduced cough (both frequency and severity) and sputum viscosity more quickly and more effectively than placebo and reduced the adhesivity of sputum more effectively than ambroxol 30mg twice daily. Co-administration of erdosteine and amoxicillin in patients with acute infective exacerbation of chronic bronchitis resulted in higher concentrations of the antibiotic in the sputum, leading to earlier and more pronounced amelioration of clinical symptoms compared with placebo. Erdosteine is associated with a low incidence of adverse events, most of which are gastrointestinal and generally mild.